For Immediate Release
Chicago, IL –August 21, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Estee Lauder EL, Becton, Dickinson BDX, Applied Materials AMAT, Regeneron REGN and HollyFrontier HFC.
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Estee Lauder; Becton, Dickinson and Applied Materials
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features updated research reports on 16 major stocks, including Estee Lauder, Becton, Dickinson and Applied Materials. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Estee Lauder’s shares are up +43.5% in the past year, outperforming the Zacks Cosmetics industry, which is up +25.9% over the same period. The Zacks analyst thinks that this is largely attributable to the company’s robust sales and earnings history, backed by growth across most brands as well as sales channels.
The trend continued in the fourth quarter of fiscal 2019, wherein the top and the bottom line surpassed estimates and rose year on year. Performance in the quarter and fiscal 2019 was supported by growth in emerging markets, strong travel retail and online sales. Additionally, management provided an optimistic view for fiscal 2020 and for the first quarter.
However, the company is mindful regarding certain headwinds such as soft retail trends in the United States and the U.K., costs related to Brexit, impact of tariffs in China as well as moderation of sales in China and travel retail network. Moreover, adverse currency rates are a concern.
(You can read the full research report on Estee Lauder here >>>).
Shares of Becton, Dickinson have outperformed the Zacks Dental Supplies industry in the past year, losing -0.6% vs. -5.3%. Becton, Dickinson, also known as BD, exited the fiscal third quarter on a strong note. The Zacks analyst likes the solid show by the core BD Medical and Interventional units.
Domestic revenues increased year over year in the quarter under review, driven by segmental strength. Growth was observed in China and EMEA. Expansion in gross and operating margins is another encouraging factor. BD kept its fiscal 2019 guidance intact. However, sluggishness in the core Life Sciences unit raises concern. International sales also declined in the quarter.
Contraction in operating margins is a concern. Management expects unfavorable foreign currency to partially mar BD’s bottom line in fiscal 2019. Stiff competition in the MedTech space adds to the company’s woes.
(You can read the full research report on Becton, Dickinson here >>>).
Applied Materials’ shares have outperformed the Zacks Semiconductor Equipment - Wafer Fabrication industry in the past three months (+14% vs. +11.8%). Applied Materials reported fiscal third quarter results wherein both earnings and revenues topped the estimates.
The company witnessed solid customer spending in foundry and logic, thanks to IoT, communications, automotive, power and sensor applications. The company also experienced solid momentum across United States and Taiwan during the reported quarter. The Zacks analyst remains optimistic about the price elasticity of NAND, which is expected to bolster NAND customer spending in the near term.
The company’s expanding etch footprint bodes well for its semiconductor portfolio. However, market uncertainties remain a headwind. Softness in semiconductor and display markets on account of slowdown in memory and display customers’ spending is major concern.
(You can read the full research report on Applied Materials here >>>).
Other noteworthy reports we are featuring today include Regeneron and HollyFrontier.
Legalizing THIS Could Be Even Bigger than Marijuana
Americans spend an estimated $150 billion in this industry every year… more than twice as much as they spend on marijuana.
Now that 8 states have fully-legalized it (with several more states following close behind), Zacks has identified 5 stocks that could soar in response to the powerful demand. One industry insider described the future as “mind-blowing” – and early investors can still get in ahead of the surge.
See these 5 “sin stocks” now >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Estee Lauder Companies Inc. (EL) : Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
Becton, Dickinson and Company (BDX) : Free Stock Analysis Report
HollyFrontier Corporation (HFC) : Free Stock Analysis Report
Applied Materials, Inc. (AMAT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research